WeTrials
Recruiting

Phase 2 Trial Utilizing Zanubrutinib in Patients With Diffuse Large B-cell Lymphoma and MYD88 L265P Mutations, CD79B Mutations, NOTCH1 Truncation or Who Are CD5+ by IHC.

What is this study?

This study is testing a targeted cancer medicine called zanubrutinib for people with a fast-growing blood cancer called diffuse large B-cell lymphoma. Researchers want to see how well this medicine works for patients who have specific genetic markers in their cancer cells.

Who can participate?

You may be able to join if you are 18 or older, have a confirmed diagnosis of this specific lymphoma with certain gene changes, and have only had one previous round of standard chemotherapy. There are some health conditions, like recent heart issues or cancer that has spread to the brain, that mean you cannot participate.

What will happen?

Participants in this study will receive the targeted cancer medicine zanubrutinib, which is designed to block the signals that cancer cells need to grow. You will also have regular check-ups and scans to see how your tumor is responding to the treatment.

Where and when?

This study is currently recruiting participants and takes place in Richmond, Virginia, United States.

Key Points
  • 1Testing a targeted cancer medicine called zanubrutinib
  • 2For adults with a specific type of fast-growing blood cancer
  • 3Currently recruiting patients in Richmond, Virginia

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Diffuse Large B-cell LymphomaDLBCL - Diffuse Large B Cell Lymphoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.